Drug Type Immune stimulating antibody conjugate (ISAC) |
Synonyms- |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC12H16N2O3 |
InChIKeyIBLSXJXHUXUHIM-UHFFFAOYSA-N |
CAS Registry104676-09-7 |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United Kingdom | 13 Mar 2023 |






